Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
IVAN....BAM UP 9.47% today
AMR right at 52wk low also known as american airlines this one should run even if economy tanks.
XOMA near 52wk low at $2.36 has a fantastic pipeline and is a strong buy in my book.Very up and down reading chart and is currently down.
WAC .....This will be my last not so bottom pick.
WAC is a mortgage/financial company that is soooo under the radar.Currently buying greentree financial for 1.1 billion.
o/s 25million pps 17+ and buying a company with 36 billion in outstanding loans.
WST...Its a higher priced pharma service company with HUGE potential.I see its pps near $60 by years end as long as the economy holds..
Jun. 15, 2011 (Business Wire) -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, hosted a groundbreaking ceremony to mark the start of construction for a compression molding plant in the Shanghai Qingpu Industrial Zone (SQIZ) in China. The new plant will be adjacent to West’s injection molding facility that was dedicated in September 2009.
When completed, the plant will manufacture components used for pharmaceutical packaging, supplying customers primarily in China and the Asia-Pacific region. The 11,900-square-meter facility is expected to begin production in January 2013.
IVAN looks to be very close to bottom.Im not sure why its fallen so much in the past two days.I love it at $1.69 heck I love it at $2 so one more down day or a stationary day and Im in.Could be a big runner on monday!
Here is some hopeful news on ALXA...
We remind investors that the previous North American deal with Biovail included $40 million upfront. We expect that a new deal for the global rights to AZ-004 will include a similar upfront payment, with potential backend milestones to include approvals in territories outside the U.S. We are optimistic that something gets done around the NDA filing. We would not be surprised to see a deal prior to the actual filing in July 2011 so that Alexza’s partner can be involved in the submission. This is yet another potential major catalyst for the shares in 2011
Sorry to tell ya bout this one late.Or maybe your in but ALXA is rocking and it prob not too late to grab some but it has run two days in a row now.I will post here some pics in the future.
sure and here too thx..............
Any interest in being an assistant on SNSS board??
looks like snss runs today http://stockcharts.com/h-sc/ui?s=SNSS jmo.
snss is getting hot under 3.00 is still nice target is 8.00 mine is more..............lol
da dip can't stop the push up on snss this thing going wild....
snss hit high of 2.20 closed at 2.14 if snss breaks 2.35 sit back and ride the money train.........
2.05 nice pick up on snss before it moves one year target 8.00 or more........
Millennium Pharmaceuticals and Sunesis Pharmaceuticals Announce Collaboration for Kinase Inhibitors in Oncology
Date : 04/05/2011 @ 7:00AM
Source : GlobeNewswire Inc.
Stock : Sunesis Pharmaceuticals, Inc.; Millennium: The Takeda Oncology C (SNSS)
Quote : up.gif 2.1499 0.2049 (10.53%) @ 1:23PM
<a href='http://as1.investorshub.com/oasis/oasisc.php?s=362&w=300&h=250& ;ord=1302024234&t=_blank&k=' target='_blank' rel='nofollow'> <img src='http://as1.investorshub.com/oasis/oasisi.php?s=362&w=300&h=250& ord=1302024234&t=_blank&k=' border='0' width='300' height='250' /> </a>
Millennium Pharmaceuticals and Sunesis Pharmaceuticals Announce Collaboration for Kinase Inhibitors in Oncology
Sunesis Pharmaceuticals, Inc. (MM) (NASDAQ:SNSS)
Intraday Stock Chart
Today : Tuesday 5 April 2011
Click Here for more Sunesis Pharmaceuticals, Inc. (MM) Charts.
Sunesis Receives a $4M Payment
Sunesis to Host Conference Call Today, April 5th at 10:00 AM Eastern Time
Millennium: The Takeda Oncology Company and Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced a license agreement for the development of Sunesis' oral, selective pan-Raf kinase inhibitor and one additional undisclosed kinase inhibitor program in oncology.
These programs were part of Sunesis' 2004 multi-kinase inhibitor collaboration with Biogen Idec. Following Biogen Idec's November 2010 announcement to focus on neurology and spin out or outlicense its oncology assets, Millennium acquired two of these oncology assets and will continue the development of these in collaboration with Sunesis. Biogen Idec and Sunesis are continuing a separate collaboration focused on a unique preclinical kinase inhibitor program involved in immunology.
"We are very excited to be working with Millennium, a company that focuses on developing first-in-class and best-in-class oncology compounds," stated Daniel Swisher, Chief Executive Officer of Sunesis. "We look forward to Millennium's transition of the pan-Raf kinase investigational agent into clinical studies, while we continue to focus our resources and attention on our ongoing Phase 3 VALOR trial for vosaroxin in AML."
"These kinase inhibitor programs represent an important addition to our portfolio and reflect our strategy to develop novel oncology therapies by targeting the underlying pathways of the disease process," said Nancy Simonian, M.D., Chief Medical Officer, Millennium. "In addition, the Raf kinase inhibitor investigational agent offers a compelling development opportunity as it targets a clinically validated pathway. We look forward to building on the strong preclinical dataset as we advance this program into clinical trials."
Non-clinical data from the oral and selective pan-Raf inhibitor were presented at the EORTC-NCI-AACR meeting in November 2010. Data were presented that demonstrated potent pan-Raf kinase inhibition in biochemical kinase assays. Data were also presented that showed profound antitumor activity in both large B-Raf mutant melanoma tumor models, tumor models of B-Raf wild-type melanoma and other B-Raf wild-type tumor types.
Under the terms of the agreement with Biogen Idec and Millennium, Sunesis has received a $4 million upfront payment from Millennium. Sunesis continues to be eligible to receive up to $60 million in pre-commercial milestone program payments and royalties on sales of future collaboration products. In addition, Sunesis has retained its future co-development and co-promotion rights.
"We are delighted to transition our collaboration with Sunesis on these oncology programs to Millennium, a world-class oncology organization," said Steven Holtzman, Executive Vice President of Corporate Development at Biogen Idec. "We look forward to seeing the oncology programs progress under Sunesis and Millennium's new collaboration, as we continue to drive forward our partnership with Sunesis on our immunology program."
Conference Call Information
Sunesis will host a conference call on April 5, 2011, 10:00 a.m. Eastern time to discuss the license agreement. The call can be accessed by dialing 866.831.6267 (U.S. and Canada) or 617.213.8857 (international) and entering the passcode 12246875. To access the live audio webcast, or the subsequent archived recording, visit the "Investors and Media - Calendar of Events" section of the Sunesis website at www.sunesis.com. The webcast will be recorded and available for replay on Sunesis' website for two weeks.
About Raf Kinase Program
The Raf kinases (A-Raf, B-Raf and C-Raf) are key regulators of cell proliferation and survival within the mitogen-activated protein kinase (MAPK) pathway. The MAPK pathway is frequently disregulated in human cancers, often via activating mutations of Ras or Raf.
About Millennium
Millennium: The Takeda Oncology Company, a leading biopharmaceutical company based in Cambridge, Mass., markets a first-in-class proteasome inhibitor in the US, and has a robust clinical development pipeline of global product candidates. Millennium Pharmaceuticals, Inc. was acquired by Takeda Pharmaceutical Company Ltd. in May, 2008. The Company's research, development and commercialization activities are focused in oncology. Additional information about Millennium and Takeda are available through their respective websites.
About Takeda
Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, www.takeda.com.
About Sunesis Pharmaceuticals
Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, vosaroxin, in multiple indications to improve the lives of people with cancer. For additional information on Sunesis, please visit www.sunesis.com.
This press release contains forward-looking statements, including statements related to the respective collaborations between Millennium: The Takeda Oncology Company and Sunesis and between Biogen Idec and Sunesis. These forward-looking statements are based upon current expectations and actual results and the timing of events could differ materially from those discussed in such forward-looking statements as a results of risks and uncertainties, which include, without limitation, risks related to the timing of the development of products under the collaborations, the achievement of milestones, the ability and willingness of Millennium or Biogen Idec to progress collaboration compounds and for Sunesis to receive milestone payments, royalties and co-promotion and co-development rights. These and other risk factors are discussed under "Risk Factors" and elsewhere in the companies' most recent annual and quarterly reports. The companies expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the companies' expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
The Sunesis Pharmaceuticals, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8773
SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.
MILLENNIUM and the logo are trademarks of Millennium Pharmaceuticals, Inc.
CONTACT: Investor and Media Inquiries:
Manisha Pai
Millennium Pharmaceuticals, Inc.
617-551-7877
Investor Inquiries:
Eric Bjerkholt
Sunesis Pharmaceuticals Inc.
650-266-3717
Media Inquiries:
David Pitts
Argot Partners
212-600-1902
Company News
SNSSD
Sunesis Pharmaceuticals, Inc. NASDAQ-CM
Back to Headlines | Print Version | ShareThis
Sunesis to Join Panel Discussion at the RBC Capital Markets' Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2011 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSSD) a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers, today announced that Daniel Swisher, Chief Executive Officer of Sunesis, will be participating in a panel discussion titled "Phase III and Beyond" at the upcoming RBC Capital Markets' Healthcare Conference on Thursday, March 3, 2011 at 9:00 A.M. Eastern Time at the New York Palace Hotel.
A live webcast of the panel discussion will be available on the Sunesis website at http://ir.sunesis.com. A replay of the webcast will be archived on the "Calendar of Events" page in the Investors and Media section of the Sunesis website for two weeks.
About Sunesis Pharmaceuticals
Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, vosaroxin, in multiple indications to improve the lives of people with cancer. For additional information on Sunesis, please visit http://www.sunesis.com.
The Sunesis Pharmaceuticals, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8773
SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.
CONTACT: Investor and Media Inquiries:
David PittsArgot Partners
212-600-1902
Eric Bjerkholt
Sunesis Pharmaceuticals, Inc.
650-266-3717
Source: Sunesis Pharmaceuticals, Inc.
Read more: http://www.nasdaq.com/aspx/company-news-story.aspx?storyid=201102240730primzoneusprx___214502&title=sunesis-to-join-panel-discussion-at-the-rbc-capital-markets-healthcare-conference#ixzz1FKWQPniX
Director, Data Management
Department: Clinical Development
Code: 02-11
The Director, Data Management will be responsible for all activities related to clinical data management, playing a vital role in progressing vosaroxin, our lead product candidate, to NDA for the treatment of first relapsed or refractory acute myeloid leukemia. The director will provide data management oversight for VALOR, the recently initiated pivotal phase 3 study for this indication, as well as for several phase 2 studies that are important components of the vosaroxin program. The position requires experience in overseeing data management throughout clinical development, and will entail crossfunctional collaboration with internal Sunesis teams, external vendors, and CRO partners. This critical role demands a highly motivated team player who is knowledgeable and solution-oriented in managing this domain, and who will develop plans, identify risks and recommend mitigation strategies to maintain program timelines.
http://www.gosolarusa.com/investors.html next winner just see.
started nice well next week could be it you never know for sure lol.
feel like banging my head but snss is a banker pass it on...sell sswc its all a scam............
SNSS
SUNESIS PHARMACE
Watch SNSS CAPS Rating 5/5 Stars
$0.47 $-0.01 (-3.08%)
there are alot of mm's waiting on snss man...like 38 plus... if they light this up..........wow!!!!!!!!!!!!!
snss on drop watch this if it breaks .55 she will run hard now .46
http://stockcharts.com/h-sc/ui?s=EAG think its time she just may.
cfw going to see new lowes jmo but now .30 may .18/.20 watching this one and eag .15 junk could be a suprize....
Usefull links below:
NEWS: http://www.purepennies.com/otcbb_news.shtml
COMPANY INFO: http://www.pinksheets.com/index.jsp
STOCK HISTORY: http://www.thesubway.com/companydata.asp
CHARTS: http://www.stockcharts.com
HOW TO UNDERSTAND LEVEL 2 FOR NEWBIES:
PART 1: www.qualitystocks.net/videocharts.php
PART 2: www.qualitystocks.net/videocharts.php
Scanners / Paper Trading:
http://www.acmechart.com/ Amazing!!! new program...Simply Amazing!!! level 2 and much more for low price!!!
http://www.microcaptrade.com/index.html
http://www.optionsxpress.com/paper_trading.asp
RULES OF SHARE BUYBACKS
According to SEC Rule 10b-18:
1 One Broker-Dealer per Day: The company repurchasing shares may not use more than one broker or dealer to acquire the shares per each day.
2 Timing of Purchase: A repurchase may not be the first trade of the day. Repurchases may not be made in the last ten minutes of the trading day. These rules do not apply to over-the-counter securities.
3 Purchase Price: A repurchase may not be bid at a price higher than the highest independent bid or last price of the last trade.
4 Volume: Repurchases per day may not exceed 25% of the average daily volume of the previous 4 calendar weeks. Block purchases not effected by a broker-dealer are excluded from this restriction.
http://en.wikipedia.org/wiki/Share_buyback
http://www.sec.gov/rules/final/33-8335.htm
Misc Items:
http://www.stocktalklive.net/
http://www.thehotpennystocks.com/
http://www.tradingday.com/
http://www.subpennyradio.com/
Other trading blogs:
http://finance.groups.yahoo.com/group/SHAKERZANDMOVERZ/
http://investorshub.advfn.com/boards/default.asp
http://finance.groups.yahoo.com/group/buzzingstocktips/
http://finance.groups.yahoo.com/group/otcalchemistlounge/
http://finance.groups.yahoo.com/group/rob_mack2001/
http://finance.groups.yahoo.com/group/moon2jump/
http://mybamboozle.com/
http://www.hotstockmarket.com/
http://www.stockhideout.com/
http://www.thepennystockblog.com/
http://ragingbull.quote.com/cgi-bin/static.cgi/a=index.txt&d=mainpages
http://www.thelion.com/bin/forum.cgi?tf=wall_street_pit
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |